Dynavax Technologies

DVAX58

$11.35arrow_drop_down1.30%-$0.15

DVAX58

$11.35

arrow_drop_down1.30%-$0.15

Performance History

Key Stats
Open	$11.46
Prev. Close	$11.50
EPS	0.13
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	11.33	11.58
52 Week Range	9.74	15.15

Ratios







EPS	0.13

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Dynavax Technologies (DVAX)

Dynavax Technologies Corp (DVAX) is a biopharmaceutical company focused on developing and commercializing novel vaccines for a range of diseases. The company's flagship product is HEPLISAV-B, a vaccine for the prevention of hepatitis B infection in adults. HEPLISAV-B is the first and only two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA). With a strong market position and a compelling product, Dynavax is well-positioned to capitalize on the growing demand for hepatitis B vaccines.

In addition to HEPLISAV-B, Dynavax has a robust pipeline of vaccine candidates targeting diseases such as influenza, respiratory syncytial virus (RSV), and COVID-19. The company's COVID-19 vaccine candidate, named DV281, is currently in preclinical development and shows promise in preclinical studies. This could be a significant growth driver for Dynavax in the coming years, given the ongoing global COVID-19 pandemic and the need for effective vaccines.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. Ryan Spencer
Headquarters: EmeryVille
Employees: 351
Exchange: NASDAQ

Keep an eye on Dynavax Technologies

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Dynavax Technologies's (DVAX) price per share?

The current price per share for Dynavax Technologies (DVAX) is $11.35. The stock has seen a price change of -$0.15 recently, indicating a -1.3% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Dynavax Technologies (DVAX)?

For Dynavax Technologies (DVAX), the 52-week high is $15.15, which is 33.48% from the current price. The 52-week low is $9.74, the current price is 16.53% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Dynavax Technologies (DVAX) a growth stock?

Dynavax Technologies (DVAX) has shown an average price growth of 0.41% over the past three years. It has received a score of 64 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Dynavax Technologies as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Dynavax Technologies (DVAX) stock price performance year to date (YTD)?

As of the latest data, Dynavax Technologies (DVAX) has a year-to-date price change of -21.07%. Over the past month, the stock has experienced a price change of -0.26%. Over the last three months, the change has been -0.7%. Over the past six months, the figure is -6.66%. Looking at a longer horizon, the five-year price change stands at 147.28%.

help

Is Dynavax Technologies (DVAX) a profitable company?

Dynavax Technologies (DVAX) has a net income of -$6.39M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 78.4% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 10.03% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $232.28M, although specific revenue growth data is currently not available. The gross profit is $182.12M. Operating income is noted at -$37.03M. Furthermore, the EBITDA is $20.98M.

help

What is the market capitalization of Dynavax Technologies (DVAX)?

Dynavax Technologies (DVAX) has a market capitalization of $1.49B. The average daily trading volume is 2.2M, indicating the stock's liquidity and investor engagement.